Posted by Michael Wonder on 14 Jul 2022
Marinus Pharmaceuticals sells rare paediatric disease priority review voucher for $110 million
14 July 2022 - Marinus Pharmaceuticals today announced that it has entered into a definitive agreement to sell its rare paediatric disease priority review voucher for $110 million.
Marinus was awarded the voucher in March 2022 when it received approval of Ztalmy (ganaxolone) oral suspension for the treatment of seizures associated with CDKL5 deficiency disorder, a rare form of genetic epilepsy, in patients two years of age and older.
